In the interview Paul says we were monitoring the 600 patients in the dose escalation study for retinal damage due to elmiron's retinal damage assertions... no evidence at all of any damage in our 600 patients according to Paul.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
40.0¢ |
Change
-0.020(4.76%) |
Mkt cap ! $158.9M | |||
| Open | High | Low | Value | Volume |
| 41.5¢ | 41.5¢ | 40.0¢ | $104.0K | 256.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 41244 | 40.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 40.5¢ | 7556 | 1 |
View Market Depth
| Last trade - 16.10pm 21/07/2025 (20 minute delay) ? |
| PAR (ASX) Chart |